Therapy-Related Core Binding Factor Acute Myeloid Leukemia

References

• AppelbaumFR, KopeckyKJ, TallmanMSet al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br. J. Haematol. 135(2), 165–173 (2006).
   PubMed Web of Science ®Google Scholar
• GustafsonSA, LinP, ChenSSet al. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am. J. Clin. Pathol. 131(5), 647–655 (2009).
   PubMed Web of Science ®Google Scholar
• SolhM, YoheS, WeisdorfD, UstunC. Core-binding factor acute myeloid leukemia: heterogeneity, monitoring, and therapy. Am. J. Hematol. 89(12), 1121–1131 (2014).
   PubMed Web of Science ®Google Scholar
• DuployezN, Marceau-RenautA, BoisselNet al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood 127(20), 2451–2459 (2016).
   PubMed Web of Science ®Google Scholar
• ParkS, ChoiH, KimHJet al. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. Ann. Hematol. 97(6), 955–965 (2018).
   PubMed Web of Science ®Google Scholar
• BorthakurG, LinE, JainNet al. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14), 3217–3221 (2009).
   PubMed Web of Science ®Google Scholar
• SmithSM, le BeauMM, HuoDet al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102(1), 43–52 (2003).
   PubMed Web of Science ®Google Scholar
• KernW, HaferlachT, SchnittgerS, HiddemannW, SchochC. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J. Clin. Oncol. 22(12), 2510–2511 (2004).
   PubMed Web of Science ®Google Scholar
• TakeyamaK, SetoM, UikeNet al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int. J. Hematol. 71(2), 144–152 (2000).
   PubMed Web of Science ®Google Scholar
• FianchiL, PaganoL, PiciocchiAet al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am. J. Hematol. 90(5), E80–85 (2015).
   PubMed Web of Science ®Google Scholar
• AldossI, PullarkatV. Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?Leuk. Res. 36(12), 1547–1551 (2012).
   PubMed Web of Science ®Google Scholar
• KantarjianHM, KeatingMJ, WaltersRSet al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J. Clin. Oncol. 4(12), 1748–1757 (1986).
   PubMed Web of Science ®Google Scholar
• KayserS, DöhnerK, KrauterJet al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7), 2137–2145 (2011).
   PubMed Web of Science ®Google Scholar
• SchlenkRF, BennerA, KrauterJet al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J. Clin. Oncol. 22(18), 3741–3750 (2004).
   PubMed Web of Science ®Google Scholar
• BorthakurG, KantarjianH. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 11(6), 114 (2021).
   PubMed Web of Science ®Google Scholar
• LamK, ZhangD-E. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed). 17(3), 1120–1139 (2012).
   PubMedGoogle Scholar
• QuesnelB, KantarjianH, BjergaardJPet al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J. Clin. Oncol. 11(12), 2370–2379 (1993).
   PubMed Web of Science ®Google Scholar
• SlovakML, BedellV, PopplewellL, ArberDA, SchochC, SlaterR. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: Report from an International Workshop. Genes Chromosomes Cancer 33(4), 379–394 (2002).
   PubMed Web of Science ®Google Scholar
• FaberZJ, ChenX, GedmanALet al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat. Genet. 48(12), 1551–1556 (2016).
   PubMed Web of Science ®Google Scholar
• ThielVN, GiaimoBD, SchwarzPet al. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation. Leukemia. 31(11), 2491–2502 (2017).
   PubMed Web of Science ®Google Scholar
• KellyLM, GillilandDG. Genetics of Myeloid Leukemias. Annu Rev Genomics Hum Genet. 3(1), 179–198 (2002).
   PubMedGoogle Scholar
• BoisselN, LeroyH, BrethonBet al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 20(6), 965–970 (2006).
   PubMed Web of Science ®Google Scholar
• SpeckNA, GillilandDG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2(7), 502–513 (2002).
   PubMed Web of Science ®Google Scholar
• RogersHJ, WangX, XieYet al. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a bone marrow pathology group study. Am. J. Hematol. 95(7), 799–808 (2020).
   PubMed Web of Science ®Google Scholar
• KhouryJD, SolaryE, AblaOet al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 36(7), 1703–1719 (2022).
   PubMed Web of Science ®Google Scholar
• ChristenF, HoyerK, YoshidaKet al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood 133(10), 1140–1151 (2019).
   PubMed Web of Science ®Google Scholar
• JahnN, TerzerT, SträngEet al. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 4(24), 6342–6352 (2020).
   PubMed Web of Science ®Google Scholar
• AyatollahiH, ShajieiA, SadeghianMHet al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol Oncol Stem Cell Ther. 10(1), 1–7 (2017).
   PubMedGoogle Scholar
• QuanX, DengJ. Core binding factor acute myeloid leukemia: advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review). Mol Clin Oncol. 13(2), 95–100 (2020).
   PubMed Web of Science ®Google Scholar
• JawharM, DöhnerK, KreilSet al. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 33(5), 1124–1134 (2019).
   PubMed Web of Science ®Google Scholar
• HanS young, MrózekK, VoutsinasJet al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 5(10), 2481–2489 (2021).
   PubMed Web of Science ®Google Scholar
• KrauthM-T, EderC, AlpermannTet al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 28(7), 1449–1458 (2014).
   PubMed Web of Science ®Google Scholar
• VangalaRK, Heiss-NeumannMS, RangatiaJSet al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101(1), 270–277 (2003).
   PubMed Web of Science ®Google Scholar
• YinJAL, O’BrienMA, HillsRK, DalySB, WheatleyK, BurnettAK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120(14), 2826–2835 (2012).
   PubMed Web of Science ®Google Scholar
• MarcucciG, MrózekK, RuppertASet al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J. Clin. Oncol. 23(24), 5705–5717 (2005).
   PubMed Web of Science ®Google Scholar
• DöhnerH, WeiAH, AppelbaumFRet al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12), 1345–1377 (2022).
   PubMed Web of Science ®Google Scholar
• ChenG, ZhouW, GongDet al. Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia. Leuk. Lymphoma 61(5), 1168–1177 (2020).
   PubMed Web of Science ®Google Scholar
• ZhouW, ChenG, GongDet al. Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study. Leuk. Lymphoma 61(4), 820–830 (2020).
   PubMed Web of Science ®Google Scholar
• ByrdJC. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13), 4325–4336 (2002).
   PubMed Web of Science ®Google Scholar
• MosnaF, PapayannidisC, MartinelliGet al. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. Am. J. Hematol. 90(6), 515–523 (2015).
   PubMed Web of Science ®Google Scholar
• LancetJE, UyGL, CortesJEet al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J. Clin. Oncol. 36(26), 2684–2692 (2018).
   PubMed Web of Science ®Google Scholar
• ByrdJC, RuppertAS, MrózekKet al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J. Clin. Oncol. 22(6), 1087–1094 (2004).
   PubMed Web of Science ®Google Scholar
• BorthakurGM, CortesJE, RavandiFet al. Fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin (FLAG-GO) regimen results in better molecular response and relapse-free survival in core binding factor acute myeloid leukemia than flag and idarubicin (FLAG-Ida). Blood 134(Suppl. 1), 290–290 (2019).
   Google Scholar
• GandhiV, EsteyE, KeatingMJ, PlunkettW. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 11(1), 116–124 (1993).
   PubMed Web of Science ®Google Scholar
• BurnettAK, RussellNH, HillsRKet al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J. Clin. Oncol. 31(27), 3360–3368 (2013).
   PubMed Web of Science ®Google Scholar
• BurnettAK, HillsRK, MilliganDet al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29(4), 369–377 (2011).
   PubMed Web of Science ®Google Scholar
• HillsRK, CastaigneS, AppelbaumFRet al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15(9), 986–996 (2014).
   PubMed Web of Science ®Google Scholar
• CastaigneS, PautasC, TerréCet al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. The Lancet. 379(9825), 1508–1516 (2012).
   PubMed Web of Science ®Google Scholar
• BorthakurG, CortesJE, EsteyEEet al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am. J. Hematol. 89(10), 964–968 (2014).
   PubMed Web of Science ®Google Scholar
• BodduP, GurguisC, SanfordDet al. Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia. 32(12), 2698–2701 (2018).
   PubMed Web of Science ®Google Scholar
• BorthakurG, RavandiF, PatelKet al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am. J. Hematol. 97(11), 1427–1434 (2022).
   PubMed Web of Science ®Google Scholar
• KhanM, CortesJ, QiaoWet al. Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 18(1), e19–e25 (2018).
   PubMed Web of Science ®Google Scholar
• HospitalM-A, PrebetT, BertoliSet al. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood 124(8), 1312–1319 (2014).
   PubMed Web of Science ®Google Scholar
• BlumW, GarzonR, KlisovicRBet al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences. 107(16), 7473–7478 (2010).
   PubMed Web of Science ®Google Scholar
• DasM. Venetoclax with decitabine or azacitidine for AML. Lancet Oncol. 19(12), e672 (2018).
   PubMed Web of Science ®Google Scholar
• DiNardoCD, PratzK, PullarkatVet al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1), 7–17 (2019).
   PubMed Web of Science ®Google Scholar
• DiNardoCD, MaitiA, RauschCRet al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 7(10), e724–e736 (2020).
   PubMed Web of Science ®Google Scholar
• AgarwalS, KowalskiA, SchifferM, ZhaoJ, BewersdorfJP, ZeidanAM. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?Expert Rev Hematol. 14(2), 199–210 (2021).
   PubMed Web of Science ®Google Scholar
• PollyeaDA, PratzK, LetaiAet al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow‐up from a phase 1b study. Am. J. Hematol. 96(2), 208–217 (2021).
   PubMed Web of Science ®Google Scholar
• VulajV, PerissinottiAJ, UebelJRet al. The FOSSIL Study: FLAG or standard 7 + 3 induction therapy in secondary acute myeloid leukemia. Leuk. Res. 70, 91–96 (2018).
   PubMed Web of Science ®Google Scholar
• HölleinA, JerominS, MeggendorferMet al. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. Leukemia. 32(10), 2270–2274 (2018).
   PubMed Web of Science ®Google Scholar
• ChenW, XieH, WangHet al. Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS One. 11(1), e0146614 (2016).
   PubMed Web of Science ®Google Scholar
• PaschkaP, MarcucciG, RuppertASet al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J. Clin. Oncol. 24(24), 3904–3911 (2006).
   PubMed Web of Science ®Google Scholar
• PollardJA, AlonzoTA, GerbingRBet al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115(12), 2372–2379 (2010).
   PubMed Web of Science ®Google Scholar
• JourdanE, BoisselN, ChevretSet al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121(12), 2213–2223 (2013).
   PubMed Web of Science ®Google Scholar
• CairoliR. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107(9), 3463–3468 (2006).
   PubMed Web of Science ®Google Scholar
• JonesD, YaoH, RomansAet al. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 49(2), 182–91 (2010).
   PubMed Web of Science ®Google Scholar
• ParkSH, ChiH-S, MinS-K, ParkBG, JangS, ParkC-J. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk. Res. 35(10), 1376–1383 (2011).
   PubMed Web of Science ®Google Scholar
• KroegerH, JelinekJ, EstécioMRHet al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112(4), 1366–1373 (2008).
   PubMed Web of Science ®Google Scholar
• AgrawalS, UnterbergM, KoschmiederSet al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 67(3), 1370–1377 (2007).
   PubMed Web of Science ®Google Scholar
• RagonBK, DaverN, Garcia-ManeroGet al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am. J. Hematol. 92(9), 845–850 (2017).
   PubMed Web of Science ®Google Scholar
• GuièzeR, RennevilleA, CayuelaJ-Met al. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia. 24(7), 1386–1388 (2010).
   PubMed Web of Science ®Google Scholar
• PaschkaP, SchlenkRF, WeberDet al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11–08 trial. Leukemia. 32(7), 1621–1630 (2018).
   PubMed Web of Science ®Google Scholar
• MarcucciG, GeyerS, LaumannKet al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10.01. Blood Adv. 4(4), 696–705 (2020).
   PubMed Web of Science ®Google Scholar
• KonumaT, KondoT, MasukoMet al. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplant. 56(11), 2779–2787 (2021).
   PubMed Web of Science ®Google Scholar
• SenapatiJ, ShoukierM, Garcia‐ManeroGet al. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am. J. Hematol. 97(5), 574–582 (2022).
   PubMed Web of Science ®Google Scholar
• WitherspoonRP, DeegHJ, StorerB, AnasettiC, StorbR, AppelbaumFR. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J. Clin. Oncol. 19(8), 2134–2141 (2001).
   PubMed Web of Science ®Google Scholar
• ArmandP, KimHT, DeAngeloDJet al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biology of Blood and Marrow Transplantation. 13(6), 655–664 (2007).
   PubMed Web of Science ®Google Scholar
• SpinaF, AlessandrinoPE, MilaniRet al. Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. Leuk. Lymphoma 53(1), 96–102 (2012).
   PubMed Web of Science ®Google Scholar
• DöhnerH, EsteyE, GrimwadeDet al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4), 424–447 (2017).
   PubMed Web of Science ®Google Scholar
• YalnizFF, PatelKP, BashirQet al. Significance of minimal residual disease monitoring by real‐time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10), 2183–2192 (2020).
   PubMed Web of Science ®Google Scholar
• BegnaKH, XuX, GangatNet al. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7 + 3.”. Blood Cancer J. 12(4), 55 (2022).
   PubMed Web of Science ®Google Scholar
• CapriaS, TrisoliniSM, DiverioDet al. Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges. Int. J. Hematol. 116(4), 586–593 (2022).
   Web of Science ®Google Scholar
• KayserS, DöhnerK, KrauterJet al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7), 2137–2145 (2011).
   PubMed Web of Science ®Google Scholar
• WangT, ChenS, ChenJet al. Allogeneic hematopoietic stem cell transplantation improved survival for adult core binding factor acute myelogenous leukemia patients with intermediate- and adverse-risk genetics in the 2017 European LeukemiaNet. Transplant Cell Ther. 27(2), 173.e1–173.e9 (2021).
   PubMedGoogle Scholar
• QinY-Z, JiangQ, WangYet al. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. Blood Cancer J. 11(4), 67 (2021).
   PubMed Web of Science ®Google Scholar